Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Moleculin Biotech, Inc. (NASDAQ: MBRX).

Full DD Report for MBRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: MBRX)

BT, NXPI among top gainers
SELLAS Life Sciences (NASDAQ: SLS ) +20%  on positive analyst action . More news on: SELLAS Life Sciences Group, Inc., Attunity Ltd, Floor & Decor Holdings, Inc., Stocks on the move, , Top stock market news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 09:27
Moleculin Bio up 12% premarket on encouraging WP1066 data
Thinly traded nano cap Moleculin Biotech (NASDAQ: MBRX ) is up  12%  premarket on modestly higher volume in reaction to its announcement of encouraging results from a Phase 1 study of WP1066. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, ...
Source: SeekingAlpha
Date: November, 01 2018 08:58
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
November 1, 2018 Palm Beach, FL – (November 1, 2018) – Multiple myeloma (MM) known as a plasma cell malignancy that affects 14,000 patients per year are fueling the development and clinical activities for new therapies to treat these malignancies. Recent clinical trial resu...
Source: Financial News Media
Date: November, 01 2018 08:00
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candida...
Source: GlobeNewswire
Date: November, 01 2018 07:30
Moleculin up 27% premarket on positive preclinical WP1066 data
Thinly traded nano cap Moleculin Biotech (NASDAQ: MBRX ) is up  27%  premarket, albeit on only 990 shares, following its announcement of preclinical data on WP1066 that support its potential use in pediatric brain tumors. More news on: Moleculin Biotech, Inc., Healthcare stocks...
Source: SeekingAlpha
Date: October, 25 2018 08:28
Innovative Advancements in Brain Tumor Therapies Holding Promise for Revolutionary Treatments
October 25, 2018 Palm Beach, FL – (October 25, 2018) – Cancer has a major impact on the health and well being of individuals across the globe. Cancer is identified as one of the leading causes of death worldwide. In 2017, approximately 0.5% of the world’s population ...
Source: Financial News Media
Date: October, 25 2018 08:17
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System...
Source: GlobeNewswire
Date: October, 25 2018 07:30
Moleculin's brain cancer drug candidate begins patient dosing
Moleculin Biotech (NASDAQ: MBRX ) has initiated a Phase 1 clinical trial of a new cancer drug candidate, a small molecule compound discovered by Prof. Waldemar Priebe at The University of Texas MD Anderson Cancer Center and known as WP1066. More news on: Moleculin Biotech, Inc., Hea...
Source: SeekingAlpha
Date: September, 13 2018 08:58
Positive Clinical Trial and R&D Developments Creating Big Opportunities and Big Returns for Biotech Industry
September 13, 2018 Palm Beach, FL – (September 13, 2018) – Biotech and Big Pharma stocks have been performing very well of lat as the SPDR S&P Pharmaceuticals ETF has risen just about 15% since the beginning of 2018, compared with 8.5% gains for the S&P 500, and up ...
Source: Financial News Media
Date: September, 13 2018 07:56
Moleculin's Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson
Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- In the ongoing challenge to combat the almos...
Source: GlobeNewswire
Date: September, 13 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.401.481.581.351,748,996
2018-12-111.221.49051.691.225,689,704
2018-12-101.281.271.291.21184,564
2018-12-071.281.261.361.24223,808
2018-12-061.321.29991.33341.21274,251

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12285,497593,08548.1376Short
2018-12-111,143,1162,023,92956.4800Short
2018-12-1022,81183,60827.2833Cover
2018-12-076,85691,6337.4820Cover
2018-12-0628,405109,93125.8389Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MBRX.


About Moleculin Biotech, Inc. (NASDAQ: MBRX)

Logo for Moleculin Biotech, Inc. (NASDAQ: MBRX)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $44,580,130 - 05/17/2018
    • Authorized: 75,000,000 - 05/01/2018
    • Issue and Outstanding: 25,768,861 - 05/01/2018

     


    Recent Filings from (NASDAQ: MBRX)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: August, 13 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: August, 10 2018
    Notice from the SEC of registration effectiveness
    Filing Type: EFFECTFiling Source: edgar
    Filing Date: July, 23 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: July, 13 2018
    General form for registration of securities under the Securities Act of 1933
    Filing Type: S-1Filing Source: edgar
    Filing Date: July, 12 2018
    Post-effective amendment to an S-8 filing
    Filing Type: S-8 POSFiling Source: edgar
    Filing Date: June, 27 2018
    Securities offered to employees under employee benefit plans
    Filing Type: S-8Filing Source: edgar
    Filing Date: June, 25 2018
    Prospectus filed under Rule 424(b)(5)
    Filing Type: 424B5Filing Source: edgar
    Filing Date: June, 21 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: June, 21 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: June, 20 2018

     

     


    Daily Technical Chart for (NASDAQ: MBRX)

    Daily Technical Chart for (NASDAQ: MBRX)


    Stay tuned for daily updates and more on (NASDAQ: MBRX)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: MBRX)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MBRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MBRX and does not buy, sell, or trade any shares of MBRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/